GANX

Gain Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel small molecule therapeutics for rare and common diseases. The company's proprietary drug discovery platform, Magellan, uses computational methods and structural biology to identify allosteric binding sites on disease-related proteins. Gain Therapeutics is developing treatments for lysosomal storage disorders, including Gaucher disease and Parkinson's disease. The company's approach aims to create first-in-class or best-in-class oral therapies that can modulate protein function and restore cellular homeostasis.